BMY Jun 2025 35.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:38AM EDT. Market open.
Loading interactive chart…
- Business Wire
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
PRINCETON, N.J., June 13, 2024--U.S. FDA Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive....
- Zacks
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- Zacks
Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know
Bristol Myers Squibb (BMY) reachead $43.02 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.
© 2024 Yahoo. All rights reserved.